GLP-1 RAs are a class of pharmacological agents that mimic the action of endogenous GLP-1 and have been approved by the FDA and EMA for the treatment of T2DM and obesity (Table 1) [27,28]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.